Doxorubicin-eluting beads - BTG

Drug Profile

Doxorubicin-eluting beads - BTG

Alternative Names: DC Bead; DEBDOX; Doxorubicin-loaded DC Bead LUMI™; E7040; Embolic bead; LifePearl; PRECISION Bead

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocompatibles International; Eisai Co Ltd
  • Developer Biocompatibles International; BTG; Eisai Co Ltd; SciClone Pharmaceuticals; Terumo
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatocellular carcinoma; Vascular disorders
  • No development reported Lung cancer

Most Recent Events

  • 12 Mar 2018 BTG and Biocompatabilities International plans a clinical trial for Hepatocellular carcinoma in April 2018 (NCT03452553)
  • 01 Mar 2017 No development reported - Phase-II for Hepatocellular carcinoma in USA (Intra-arterial)
  • 29 Sep 2015 Doxorubicin eluting beads receives approval for Hypervascular tumours in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top